Sarah-Jane Dawson

This article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) This biography of a living person relies too much on references to primary sources. Please help by adding secondary or tertiary sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately, especially if potentially libelous or harmful. (January 2018) (Learn how and when to remove this template message) This biography of a living person needs additional citations for verification. Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately, especially if potentially libelous or harmful. Find sources:  –  ·  ·  · scholar · JSTOR (November 2017) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Sarah-Jane Dawson FAHMS is an Australian clinician-scientist. She is a consultant medical oncologist and head of the Molecular Biomarkers and Translational Genomics Laboratory^[1] at the Peter MacCallum Cancer Centre in Melbourne. Her current research interests are focused on the development of noninvasive blood-based biomarkers ('liquid biopsies')^[2] for clinical application, including early detection, risk stratification and disease monitoring in cancer management.

Education[]

Dawson obtained her medical degree from the University of Melbourne in 1998, and trained as a medical oncologist in Melbourne, Australia. She completed her PhD at the University of Cambridge and performed postdoctoral studies at the , UK. She returned to Melbourne in 2014 to lead a research laboratory at the Peter MacCallum Cancer Centre.^[1] Dawson was elected Fellow of the Australian Academy of Health and Medical Sciences in 2020.^[3]

Scientific profile[]

Dawson has international recognition for her contributions to . A major focus of her current research involves the study of cell-free circulating tumour DNA in patients with cancer.^[4] Many cancers shed small amounts of DNA (called circulating tumour DNA) into the patient's bloodstream which can be measured for clinical applications in cancer management. Dawson's recent research has shown the application of circulating tumour DNA testing for disease monitoring in various cancer types. She has received ongoing support from high-profile Australian organisations including the National Health and Medical Research Council (NHMRC), National Breast Cancer Foundation, and Australian Cancer Research Foundation.

References[]

External links[]

• Selected Publications